Docetaxel as a radiation booster for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding the chemotherapy drug docetaxel to radiation therapy works better for treating advanced head and neck cancer. It is for people whose cancer has not spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have squamous cell carcinoma of the head and neck (a type of cancer confirmed by biopsy).
- Your cancer is locally advanced (stage T3 or T4, and lymph nodes are involved, but it has not spread to distant organs).
- You are eligible for radiation therapy (your doctor says you can safely have it).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of giving radiation therapy, called adaptive radiation boost, for people with head and neck cancer. The goal is to see if this approach can better target the cancer and possibly improve outcomes.
This trial tests a precise type of radiation called stereotactic radiosurgery for people with head or neck tumors. It may be an option for those who need radiation or chemoradiation as their main treatment or after surgery.
This trial tests a new way to give radiation therapy for head and neck cancer. By using a special PET scan to guide where higher radiation doses are given, doctors hope to improve treatment while reducing side effects. It is for people whose cancer is not early-stage and who will receive standard radiation therapy.
This trial tests a combination of three drugs (docetaxel, nimotuzumab, and pucotenlimab) for people with head and neck cancer that has come back or spread. It is for those who have already tried and failed treatments like immunotherapy and platinum chemotherapy.
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
This trial compares radiation therapy alone versus radiation therapy plus a targeted drug called nimotuzumab for people with advanced head and neck cancer who cannot take cisplatin chemotherapy. The goal is to see if adding nimotuzumab improves outcomes.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.